Comparing inspiratory muscle training and Baduanjin exercises for heart health

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study compares the effects of inspiratory muscle training and Baduanjin exercises on pulmonary function, exercise capacity, and quality of life in patients with hypertrophic cardiomyopathy. It involves three groups: a control group, an inspiratory muscle training group using a specialized device, and a Baduanjin exercise group participating in a structured exercise program. Each intervention lasts for 8 weeks, with the aim of identifying effective methods to improve health outcomes for these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Myocardial thickness in any region of the left ventricle is 15 mm or more on echocardiography or cardiac MRI
* Clinically and hemodynamically stable (patients with NYHA Class I and II)
* Patients over 18 years of age
* Patients who provide informed consent

Exclusion Criteria:

* Acute decompensated heart failure
* Decreased ejection fraction (\<40%)
* Unstable angina pectoris
* Significant coronary artery disease (CAD)
* Severe renal dysfunction (estimated glomerular filtration rate \<30 mL/min/m²)
* Uncontrolled hypertension (despite medication)
* Severe valve disease (moderate-severe aortic stenosis, advanced mitral regurgitation)
* Severe neurological disorders causing autonomic dysfunction
* Cognitive impairment that prevents communication
* Recent fractures, osteoporosis, presence of tumors, pregnancy, or back and spine problems

Where it's running

• Istanbul University-Cerrahpasa (IUC) Cardiology Institute
  Istanbul, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Rengin Demir, Prof
• Email: rengindemir@yahoo.com
• Phone: +902124592000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TRIFORMIS RESILIA heart valve real-world results in tricuspid disease

  A real-world, observational study to see how the Edwards TRIFORMIS RESILIA tricuspid heart valve performs in adults needing tricuspid valve replacement.

  Recruiting Edwards Lifesciences · Carmel, Indiana · NCT07684313

• Women-Focused Education in Cardiac Rehab

  This pilot test checks if a women-focused education program added to standard cardiac rehab is feasible and helps women improve heart-health knowledge, quality of life, and healthy behaviors.

  Recruiting University Health Network, Toronto · Barrie, Ontario and 2 other locations · NCT07550036

• Mavacamten for symptomatic obstructive hypertrophic cardiomyopathy in Chinese adults

  This project will test how well mavacamten works for Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy when used in everyday clinical care.

  Recruiting at 10 sites Bristol-Myers Squibb · Beijing, Beijing Municipality and 14 other locations · NCT07361289

• Transitioning people with recurrent pericarditis to KPL-387 monotherapy dosing and administration

  This trial will try switching people with well-controlled recurrent pericarditis from their current therapies to KPL-387 alone for up to 16 weeks to see if symptoms and inflammation stay controlled and the drug is tolerable.

  Recruiting at 48 sites Phase 2 Kiniksa Pharmaceuticals International, plc · Phoenix, Arizona and 47 other locations · NCT07288216

• Coronary CT angiography–guided calcium modification during PCI for calcified coronary artery disease

  This study will see if using CT angiography to plan calcium treatment before stenting helps people with flow-limiting, calcified coronary artery disease have better stent results and faster procedures compared with the usual ultrasound-guided PCI while keeping similar safety.

  Recruiting at 10 sites Fundación EPIC · Boston, Massachusetts and 14 other locations · NCT07286578

• Freesolve resorbable magnesium scaffold vs. Xience stent for up to two new heart artery lesions

  This trial tests whether the Freesolve resorbable magnesium scaffold works as well as the Xience drug-eluting stent for treating up to two new coronary artery lesions in adults.

  Recruiting at 3 sites Teleflex · Washington D.C., District of Columbia and 2 other locations · NCT07258290

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.